Filing Flows › Xilio Therapeutics (XLO) › Stock forecast & fair value
Xilio Therapeutics (XLO) stock forecast and price target
Xilio Therapeutics (XLO) trades at $8.62. 2 analysts' median price target is $18.00 (+109%), from $16.00 to $20.00.
Xilio Therapeutics' latest quarter
Xilio Therapeutics, Q2 2026: revenue $18.7M (+131% year over year), operating margin -18.7%, net loss $6.4M, operating cash flow −$18.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for XLO stock?
The median of 2 analysts' 12-month targets is $18.00, +109% from $8.62; the range is $16.00 to $20.00. The average rating is strong buy.
Does Xilio Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is XLO stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.